Core Viewpoint - Huadong Medicine (000963.SZ) has received approval from the National Medical Products Administration (NMPA) for the marketing authorization of Relmapirazin Injection, a new Class 1 chemical drug developed by its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd [1] Group 1: Product Details - Relmapirazin Injection is a non-radioactive, non-iodinated fluorescent GFR tracer that requires the use of MediBeacon Inc.'s transdermal glomerular filtration rate measurement device (TGFR) [1] - The product aims to non-invasively monitor the fluorescence of an exogenous tracer over time to assess the glomerular filtration rate (GFR) in patients with impaired or normal kidney function [1]